Avalyn Pharma (AVLN) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | MLYS |
|---|---|---|
| Share price | $28.40 | $13.66 |
| Market cap | $1.26B | $1.21B |
| 1-day change | -1.05% | -3.53% |
| YTD return | — | -62.36% |
| 1-year return | — | -67.38% |
| EPS (TTM) | $-3.96 | $-4.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-154.65M |
| 52-week high | $40.17 | $44.13 |
| 52-week low | $22.24 | $13.57 |
| Distance from 52-week high | -29.30% | -69.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +114.79% | +218.89% |
| Average volume | 352.95K | 1.55M |
| Shares outstanding | 44.52M | 88.56M |
| Employees | 56 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
AVLN vs MLYS FAQ
Which is bigger, Avalyn Pharma or Mineralys Therapeutics?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.21B for Mineralys Therapeutics (MLYS).
Are Avalyn Pharma and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.